Want to join the conversation?
$ARNA 2Q15 Call: Arena believes APD334 has therapeutic potential in a variety of oral immune diseases, including ulcerative colitis. Currently available treatment options have limitations in terms of long-term efficacy and side-effects, have complicated administration regimen, and often fail to induce or maintain remission.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.